Chris Sprute

Chris Sprute is an experienced professional in market access and national accounts within the healthcare industry, currently serving as the Director of National Accounts and Health Policy at Ocular Therapeutix, Inc. since August 2023. Previously, Chris worked at Abbott focusing on market access strategies for the infectious disease portfolio. Notable past roles include National Account Director positions at Braeburn and Portola Pharmaceuticals, where Chris effectively managed relationships with major payers and developed market strategies. Chris's extensive background also includes leadership roles at Eagle Pharmaceuticals and Boehringer Ingelheim, with a proven track record in payer relations and sales growth across various healthcare segments. Chris holds an MBA from the University of San Francisco and a BBA in Finance from Texas State University.